Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Abbott Earns CE Mark For FreeStyle Libre Bloodless Glucose Monitor

This article was originally published in The Gray Sheet

Executive Summary

FreeStyle Libre reads glucose levels through a interstitial fluid sensor on the back of the patient’s arm, but unlike current continuous glucose monitors does not require finger-stick calibrations.

You may also be interested in...



Abbott Gains US Approval For Pro Version Of Flash Glucose System

The FreeStyle Libre Pro is intended to provide health-care providers with an easy-to-read visual summary of a diabetic patient's glucose data. Abbott has also filed for approval with FDA for a consumer-targeted version of the device.

ADA 2014: Diabetes Players Move Closer To An Artificial Pancreas

The quest to bring an artificial pancreas to market has taken some giant steps forward recently, as major players continue to produce impressive data from clinical studies that measure the use of various insulin pumps, continuous glucose monitors (CGMs), and algorithms. Improvements in CGM sensor technology have helped move AP research, and competition is proving to be a driving force on the road to producing a commercial product that could be within two or three years from reaching the market.

Medicare Competitive Bidding Makes Big Impression On U.S. Diabetes Device Earnings

Johnson & Johnson and Abbott Laboratories each reported massive double-digit revenue drops for their U.S. diabetes product divisions in earnings reports this week, citing the impact of the national Medicare competitive bidding program for diabetes supplies. Roche had better-looking results for the most recent quarter, but also has taken a big hit from massive reimbursement cuts resulting from nationwide bidding.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT033282

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel